205744-16-7 Usage
General Description
3-Pyridinemethanamine, 2-fluoro-(9CI) is a chemical compound with the molecular formula C6H7FN2. It is also known by its CAS number 872557-68-9. 3-Pyridinemethanamine,2-fluoro-(9CI) is a derivative of pyridine and contains a fluorine substituent. It is commonly used in medicinal chemistry and pharmaceutical research as a building block for the synthesis of various organic compounds. Its properties and potential applications in organic synthesis and pharmaceutical research make it an important chemical for the development of novel drugs and biologically active compounds. Due to its potential use in drug discovery and development, 3-Pyridinemethanamine, 2-fluoro-(9CI) is a valuable compound for researchers in the pharmaceutical industry.
Check Digit Verification of cas no
The CAS Registry Mumber 205744-16-7 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 2,0,5,7,4 and 4 respectively; the second part has 2 digits, 1 and 6 respectively.
Calculate Digit Verification of CAS Registry Number 205744-16:
(8*2)+(7*0)+(6*5)+(5*7)+(4*4)+(3*4)+(2*1)+(1*6)=117
117 % 10 = 7
So 205744-16-7 is a valid CAS Registry Number.
InChI:InChI=1/C6H7FN2.HCL/c7-6-5(4-8)2-1-3-9-6/h1-3H,4,8H2
205744-16-7Relevant articles and documents
7-Substituted Purine Derivatives for Immunosuppression
-
Page/Page column 10, (2008/12/05)
The present invention provides novel purinone and related derivatives useful for the prevention and treatment of autoimmune diseases, inflammatory disease, mast cell mediated disease and transplant rejection. The compounds are of the general formula III:
PURINE AND IMIDAZOPYRIDINE DERIVATIVES FOR IMMUNOSUPPRESSION
-
Page/Page column 31, (2010/11/24)
The present invention provides novel purine and imidazopyridine derivatives useful for the prevention and treatment of autoimmune diseases, inflammatory disease, mast cell mediated disease and transplant rejection. The compounds are of the general formulas ( I ) and ( II ).
